Dow Jones
38.460,92 -42,77 (-0,11%) Nasdaq
15.712,75 +16,11 (+0,10%) Nikkei 225
37.986,75 -473,33 (-1,23%) EUR/USD
1,0705 +0,0005 (+0,04%) Bitcoin EUR
60.333,02 -2.085,55 (-3,34%) CMC Crypto 200
1.394,53 -29,57 (-2,08%)
Nanobiotix SA (0QAV.IL)
- GlobeNewswire
Voting Rights and Shares Capital of the Company
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)PARIS, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: BISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights, theoretical1Total voting rights, exercisable2
- GlobeNewswire
Nanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1 Months
Results presented in an oral presentation by Professor Christophe Le Tourneau, MD, PhD, of Institut Curie, and highlighted in two scientific sessions at the 65th Annual Meeting of the American Society for Radiation Oncology Waterfall Plot Best Observed Response in Injected Lesions Based on Investigator Assessment Final data from Study 102 Dose Expansion show that radiotherapy-activated NBTXR3 was feasible and well tolerated in elderly patients with a high burden of comorbidity (n=56)Consistently
- GlobeNewswire
NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation Oncology
Conference call and live webcast Thursday, October 5th, 2023, at 8:00 AM EDT/2:00pm CESTPARIS and CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the oral presentation of the final readout on primary objectives from Study 102 Dose Expansion—the expansion part of a Phase 1 dos
